Illumina Ventures was among the investors in the Baidu-backed diagnostics tool developer’s latest round, boosting its overall funding to $111m.
US-based home diagnostics technology developer Sherlock Biosciences received $80m in series B funding yesterday from investors including Illumina Ventures, the venture capital fund backed by genomics technology producer Illumina.
Venture capital firm Novalis LifeSciences led the round, which also featured Albany Capital, Catalio Capital Management and existing investors including Northpond Ventures and Good Ventures. The company’s funding stands at $111m since it was founded in 2019.
Sherlock is working on molecular-level diagnostic kits leveraging synthetic biology and Crispr gene-editing technology.…
